Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

HealthRX vs Ivy Rx

HealthRX
Site position #36

Higher grade

vs+10.7
Ivy Rx
Site position #201

Lower grade

The verdict

HealthRX takes it — 77.5/100 to 66.8/100.

HealthRX grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthRX’s current injection plans disclose the first charge and renewal separately. The lowest monthly equivalents require a prepaid year; a monthly subscription offers a smaller initial commitment.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueHealthRX +23
85
62
Dose & formulationEven
64
64
Clinical oversightHealthRX +5
87
82
Labs & monitoringHealthRX +29
82
53
FulfillmentHealthRX +5
86
81
Contract termsIvy Rx +12
43
55
HealthRX · left barIvy Rx · right bar

The numbers

MetricHealthRXIvy Rx
WeighScore77.5/10066.8/100
GradeC+C
Site position#36#201
Semaglutide$149 first month, then $165/month; $1,163 per 12-month subscription$175/mo (starting dose, compounded)
Tirzepatide$193 first month, then $214/month; $2,123 per 12-month subscription$275/mo (starting dose, compounded)
CoverageNot publicly listedAll 50 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
HealthRX

Site position #36 · C+

Strengths

  • Product pages publish due-today and next-charge tables
  • Medication if approved, provider review and overnight shipping are included
  • Longer plans offer a one-time purchase option without automatic renewal

Where it loses points

  • Annual headline rates require payment for 12 months upfront
  • Monthly subscription prices rise after the first payment
  • Product navigation still shows older starting prices
  • Injection supplies are not confirmed as standard inclusions
Ivy Rx

Site position #201 · C

Strengths

  • Both semaglutide and tirzepatide available
  • Compounded GLP-1 access

Where it loses points

  • Limited public information on program details

Featured provider

HealthRX

HealthRX scores 77.5/100 (C+). HealthRX’s current injection plans disclose the first charge and renewal separately. The lowest monthly equivalents require a prepaid year; a monthly subscription offers a smaller initial commitment.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard